Global markets

Japan: Is Now the Time to Invest?

Japan: Is Now the Time to Invest?

Japan went through an historic boom that peaked in the late 1980s and early 1990s. Asset prices rose at an incredible pace, with the price of land absolutely rampant, increasing by as much as 5,000 per cent between 1956 and 1986. So distorted were land prices that...

U.S. Credit Rating Downgraded by Fitch

U.S. Credit Rating Downgraded by Fitch

U.S. Credit Rating Downgraded by Fitch 10/8/2023 Fitch announced last week that it downgraded the United States’ long-term credit rating from the AAA (the highest possible rating) down to AA+ (the second highest rating). For those that are unfamiliar, Fitch is the...

SWIFT Retribution: Russian Sanctions & What It Means

SWIFT Retribution: Russian Sanctions & What It Means

This week we revisit the topic of Russia and the escalation in sanctions by the West. In particular we want to talk about the oft heard about but little known SWIFT system through which some of these sanctions are being imposed, the implications for broader markets...

4 Investing Megathemes Worth Watching

4 Investing Megathemes Worth Watching

This week we would like to offer our thoughts on certain megathemes that are impacting investment markets. Firstly, credit where it is due, this is a topic inspired by an oped in the AFR by James Thomson who summarises what he sees the recent bid by Cannon-Brookes for...

Politics, Trust and Investing: Our Greatest Risk?

Politics, Trust and Investing: Our Greatest Risk?

Growing up it was ingrained that two topics are rather taboo to discuss at the dinner table; the first being politics and the second money. So, with the hope that you’re not having dinner as you read, this week we discuss the former while touching on the latter....

Pharma: Investing in the Pipeline, Not the Products

Pharma: Investing in the Pipeline, Not the Products

This week we look to conclude the series with some insights into two more pharma companies that we believe could make for an interesting addition to investor portfolios. Both are potentially high growth and arguably further up the risk curve (if one is to define it by...

Pharma: DexCom & BMS | Can giants grow?

Pharma: DexCom & BMS | Can giants grow?

This week we continue on to the final in the pharma series by looking at specific companies that we feel are worth at least a review by investors. As elucidated last time, the categories that offer the most lucrative long-term opportunities are Oncology, Diabetes and...

Pharma: Diabetes, Cancer & Cardiovascular/Respiratory

Pharma: Diabetes, Cancer & Cardiovascular/Respiratory

This week we continue to look at the global pharmaceutical industry. More specifically, this week we will be looking to identify some of the trends and segments which may produce some more lucrative opportunities.   Before we begin, a quick recap of the main points...

Sign Up to Our Weekly Stock Insights

* Indicates required field

Name(Required)

Categories

Popular Topics